News

The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Thame Laboratories was required to issue a corrective statement to recipients of the letter at issue.

The Consultation closed on 10th October 2018. Many thanks to those who contributed.

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Pierre Fabre was publicly reprimanded in one case.

Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, PharmaMar has been publicly reprimanded and required to issue a corrective statement.

The ABPI and NHS England have issued a joint letter setting out the ambition to increase consent rates as quickly as possible for publication of payments to individuals on Disclosure UK. The letter, ​published on 22 December 2017 and signed by ABPI CEO Mike Thompson and NHSE National Director Ian Dodge,​ is now available on the ABPI website. 

PMCPA ANNUAL REPORT SHOWS A BUSY YEAR, WITH MORE COMPLAINTS IN 2016 THAN IN THE PREVIOUS TWO YEARS.

Astellas UK and Astellas Europe have brought discredit upon, and reduced confidence in, the pharmaceutical industry, in addition both have been publicly reprimanded. Pfizer Ltd, Novartis Pharmaceuticals UK Ltd and Tor Generics Ltd have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

Astellas UK and Gedeon Richter (UK) Ltd have brought discredit upon, and reduced confidence in, the pharmaceutical industry. Astellas UK has been publicly reprimanded and Gedeon Richter required to issue a corrective statement.​

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

​The ABPI Code of Practice is in the process of being updated. In the meantime, the PMCPA is working on reviewing and updating its guidance. The PMCPA Compliance Network was asked to help with this and to identify possible short and long term changes to the Code. The Review Group and the ABPI Medical Expert Network and others have also contributed to the discussion. This is part of the ongoing work to ensure that the Code and its operation remain fit for purpose.